Prolonged Response to Regorafenib in a Patient with Iodine Refractory Thyroid Cancer
| العنوان: | Prolonged Response to Regorafenib in a Patient with Iodine Refractory Thyroid Cancer |
|---|---|
| المؤلفون: | Selina K Wong, Alexander J.B. McEwan, Randeep Sangha, Donald W. Morrish, Gwen Sergenson, Diane Arndt, Quincy Chu, Adriaan Cleton, Funan Huang, Jennifer L. Spratlin, Michael B. Sawyer |
| المصدر: | Case Reports in Oncology Case Reports in Oncology, Vol 12, Iss 3, Pp 791-795 (2019) |
| بيانات النشر: | S. Karger AG, 2019. |
| سنة النشر: | 2019 |
| مصطلحات موضوعية: | 0301 basic medicine, Oncology, Sorafenib, medicine.medical_specialty, endocrine system, Case Report, lcsh:RC254-282, Thyroid cancer, Thyroid carcinoma, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Thyroid-stimulating hormone, Regorafenib, Internal medicine, medicine, Follicular thyroid cancer, Iodine-refractory, business.industry, Cancer, medicine.disease, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, 030104 developmental biology, chemistry, 030220 oncology & carcinogenesis, Lenvatinib, business, medicine.drug |
| الوصف: | Thyroid cancer is the most common type of endocrine malignancy. Cornerstones of thyroid cancer treatment include surgery, radioactive iodine ablation, and thyroid stimulating hormone suppression. The National Comprehensive Cancer Network guidelines recommend two tyrosine kinase inhibitors for thyroid cancer patients who are non-responsive to iodine: sorafenib and lenvatinib. Another oral kinase inhibitor, regorafenib, is not considered standard of care treatment for differentiated thyroid cancer. The chemical structures of regorafenib and sorafenib differ by a single fluorine atom. Given the significant improvement in progression-free survival (PFS) of sorafenib compared to placebo demonstrated in the phase 3 DECISION trial, we report on a patient with iodine-refractory follicular thyroid cancer treated with regorafenib as part of a phase 1 clinical trial. A 75 year old woman was diagnosed with follicular thyroid carcinoma in 2006 and initiated on treatment with regorafenib in 2011. She has completed 76 cycles with stable disease and pulmonary metastases 34% smaller than baseline. |
| اللغة: | English |
| تدمد: | 1662-6575 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cb1a32f10ac935e587957b6b49efbcf8Test http://europepmc.org/articles/PMC6872990Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....cb1a32f10ac935e587957b6b49efbcf8 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 16626575 |
|---|